Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
Susanna Naggie is leading a nation-wide study of ivermectin, ACTIV-6. She is also a member of the NIH panel that provided the current recommendation on the use of ivermectin in COVID-19 that is at odds with the view of leading physicians and experts in evidence-based medicine:
“There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.”
These two positions are in conflict because a recommendation to use ivermectin in COVID-19 is implicitly a recommendation to end the ACTIV-6 trial.
Naggie published “Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19” in Annals of Internal Medicine on June 19, 2021. Like most scientific journals, Annals requires the disclosure ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).